Gary K Ostrander

US Patent:

20220339140, Oct 27, 2022

Filed:

May 24, 2022

Appl. No.:

17/664693

Inventors:

- TALLAHASSEE FL, US
GARY OSTRANDER - TALLAHASSEE FL, US
GEOFFREY STUART DOW - WASHINGTON DC, US

International Classification:

A61K 31/437
G01N 33/53
G01N 33/68

Abstract:

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

US Patent:

20210380583, Dec 9, 2021

Filed:

Jun 4, 2021

Appl. No.:

17/303698

Inventors:

- TALLAHASSEE FL, US
GARY OSTRANDER - TALLAHASSEE FL, US

International Classification:

C07D 471/04

Abstract:

The invention concerns a scalable, large-scale castanospermine preparation method that yields levels of purity greater than 98% from castanospermine-containing plant sources, such as seed material.

US Patent:

20210308079, Oct 7, 2021

Filed:

Apr 2, 2021

Appl. No.:

17/301444

Inventors:

- TALLAHASSEE FL, US
GARY OSTRANDER - TALLAHASSEE FL, US

International Classification:

A61K 31/167
A61K 47/10
A61K 47/20
A61K 47/40
A61K 9/48
A61K 9/28
A61K 9/00
A61K 47/38
A61K 47/32

Abstract:

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

US Patent:

20210267952, Sep 2, 2021

Filed:

Feb 19, 2021

Appl. No.:

17/180140

Inventors:

- TALLAHASSEE FL, US
GARY OSTRANDER - TALLAHASSEE FL, US
GEOFFREY STUART DOW - WASHINGTON DC, US

International Classification:

A61K 31/437
G01N 33/68
G01N 33/53

Abstract:

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

US Patent:

20180117018, May 3, 2018

Filed:

Dec 28, 2017

Appl. No.:

15/856377

Inventors:

- Tallahassee FL, US
GARY OSTRANDER - Tallahassee FL, US

International Classification:

A61K 31/437
A61P 31/14
A61K 45/06
A61K 9/127
A61K 47/60

Abstract:

The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

US Patent:

20180066071, Mar 8, 2018

Filed:

Oct 30, 2017

Appl. No.:

15/797846

Inventors:

- TALLAHASSEE FL, US
GARY OSTRANDER - TALLAHASSEE FL, US

International Classification:

C07K 16/44
G01N 33/574
G01N 33/53

Abstract:

The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

US Patent:

20170312257, Nov 2, 2017

Filed:

May 2, 2017

Appl. No.:

15/584952

Inventors:

- Tallahassee FL, US
GARY OSTRANDER - TALLAHASSEE FL, US

International Classification:

A61K 31/437
A61K 31/33
C07D 401/02
C12P 17/12

Abstract:

The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

US Patent:

20170101481, Apr 13, 2017

Filed:

Oct 10, 2016

Appl. No.:

15/289783

Inventors:

- Tallahassee FL, US
GARY OSTRANDER - TALLAHASSEE FL, US

International Classification:

C07K 16/44
G01N 33/574
G01N 33/53

Abstract:

The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.